Menu

Pharmaceuticals

 

 

Lilly Diabetes Extends National Sponsorship of the American Diabetes Association’s Signature Tour de Cure® Cycling Event for a Second Year

, , , ,

New sponsorship of “Red Riders®”–cyclists with diabetes–added in 5 cities INDIANAPOLIS, Nov. 19, 2013 /PRNewswire/ — News Highlights: For a 2nd year, #Lilly #Diabetes supports the American Diabetes Association’s Tour de Cure cycling event to help #StopDiabetes New in 2014, #Lilly #Diabetes to support #RedRider cyclists with #diabetes in 5 cities Lilly Tour de Cure […]

American Medical Systems Announces 500th Patient Enrolled in PROPPER Registry

, , ,

Largest Prospective, Multi-Year, Physician-Led Registry Advances Understanding of Real-World Satisfaction with Penile Prostheses MINNEAPOLIS, Nov. 19, 2013 /PRNewswire/ — American Medical Systems® (AMS), Inc. an Endo Health Solutions Inc. (Nasdaq: ENDP)  subsidiary and leading provider of devices and therapies for male and female pelvic health, today announced the enrollment of the 500th patient in the largest multi-year, prospective global […]

Regina E. Dugan Appointed to Board of Directors of Varian Medical Systems

, , , , , ,

PALO ALTO, Calif., Nov. 18, 2013 /PRNewswire/ — Varian Medical Systems, Inc. (NYSE:VAR) today announced that Regina E. Dugan, Ph.D., Senior Vice President of Advanced Technology and Projects (ATAP) at Google’s Motorola Mobility LLC, has been appointed to the Varian Board of Directors, effective December 15, 2013. “We believe that Regina is eminently qualified to serve as a director […]

Mylan Launches First Generic Focalin XR® Capsules, 30 mg

, , ,

– Company awarded 180 days marketing exclusivity – PITTSBURGH, Nov. 18, 2013 /PRNewswire/ — Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. has launched Dexmethylphenidate Hydrochloride Extended-release (ER) Capsules, 30 mg, which is the first generic version of Novartis’ Focalin XR®. Mylan was the first company to have filed a substantially […]

Sangamo BioSciences Announces Presentation Of Clinical Data From Alzheimer’s Disease Program

, , , ,

Data Demonstrate Long-Term Expression of Functional Nerve Growth Factor in the Brain and Stabilization of Brain Cell Metabolic Activity RICHMOND, Calif., Nov. 15, 2013 /PRNewswire/ — Sangamo BioSciences, Inc. (NASDAQ: SGMO) announced today the presentation of positive data from the Phase 1 clinical trial of CERE-110 (AAV-NGF), a gene therapy approach designed to deliver nerve growth factor (NGF) for […]

Valeant Pharmaceuticals Announces U.S. Approval Of Luzu® Cream, 1%

, , ,

LAVAL, Quebec, Nov. 15, 2013 /PRNewswire/ — Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) announced today that its wholly owned subsidiary, Valeant Pharmaceuticals North America LLC, has received notice that the New Drug Application for Luzu® (luliconazole) Cream, 1% has been approved by the United States Food and Drug Administration (FDA). Luzu® Cream, […]

Varian Medical Systems Exhibits New Flat-Panel Digital X-ray Image Detectors Designed for High Energy Industrial and Security Applications

, , , , ,

Varian showcasing these and other X-ray imaging components at the 2013 Transport Security (TranSec) Expo in London this week LONDON, Nov. 14, 2013 /PRNewswire/ — A new flat-panel digital X-ray image detector designed especially for use in high-energy industrial and security imaging systems is among the imaging components that Varian Medical Systems (NYSE:VAR) is exhibiting at the 2013 […]

Novartis announces positive clinical trial results for novel H7N9 vaccine

, ,

85% of subjects immunologically protected after receiving second dose of investigational cell culture vaccine when combined with proven MF59® adjuvant Vaccine now in large scale production highlighting rapid response capability of novel FDA licensed cell culture technology 135 confirmed cases and 45 deaths from H7N9 virus since emergence in March according to the World Health […]

Sangamo BioSciences Announces Presentation Of First Demonstration Of In Vivo Efficacy Of Novel ZFP Therapeutic® For Huntington’s Disease

, , ,

Approach Selectively Represses Only the Disease-Causing Gene Resulting in Statistically Significant Effects on Symptoms and Other Biomarkers of Disease in Animal Models RICHMOND, Calif., Nov. 12, 2013 /PRNewswire/ — Sangamo BioSciences, Inc. (NASDAQ: SGMO) announced today that positive preclinical data from their joint program with Shire plc to develop a novel ZFP Therapeutic® approach to Huntington’s disease (HD) were presented […]

«‹ 24 25 26 27›»